Morán M
Orthopaedic Surgery Unit, Naval Medical Centre, Lima, Peru.
J Int Med Res. 1991 Mar-Apr;19(2):121-30. doi: 10.1177/030006059101900205.
In a double-blind, placebo-controlled comparative study in 60 patients with ankle sprains suffering from moderate to severe inflammation and tenderness, the efficacy and tolerability of 150 mg/day diclofenac potassium given for 7 days was superior to that of 1.2 g/day ibuprofen which was, in turn, superior to placebo. Efficacy was assessed by volumetric evaluation of inflammation of the injured ankle, tenderness on finger pressure, pain on movement and the severity of the joint injury. Patients used visual analogue scales to assess severity of pain at rest and on walking before and during treatment. Diclofenac potassium was significantly superior (P less than 0.02) to ibuprofen for all measures of efficacy (except severity of joint injury) and ibuprofen was consistently superior to placebo. No serious adverse effects were reported. In conclusion, diclofenac potassium has been demonstrated to be effective in the treatment of acute ankle sprains and it had a rapid onset of action and good tolerability.
在一项针对60名患有中度至重度炎症和压痛的踝关节扭伤患者的双盲、安慰剂对照比较研究中，连续7天每天服用150毫克双氯芬酸钾的疗效和耐受性优于每天服用1.2克布洛芬，而布洛芬又优于安慰剂。通过对受伤踝关节炎症的体积评估、手指按压时的压痛、运动时的疼痛以及关节损伤的严重程度来评估疗效。患者使用视觉模拟量表评估治疗前和治疗期间静息和行走时的疼痛严重程度。在所有疗效指标（关节损伤严重程度除外）上，双氯芬酸钾均显著优于布洛芬（P小于0.02），且布洛芬始终优于安慰剂。未报告严重不良反应。总之，双氯芬酸钾已被证明对急性踝关节扭伤有效，起效迅速且耐受性良好。
